ClinicalTrials.gg
Not yet recruitingNCT07924904Updated Nov 9, 2026

Mindfulness Meditation to Reduce Cognitive Load

An interventional study of Guided Mindfulness Meditation and Neutral Story Listening in Test Anxiety, Stress, Psychological and Cognitive Aging, sponsored by University of South Carolina. Not yet recruiting at 4 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of South Carolina · Not applicable, Interventional, and Diagnostic

Updated Nov 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

Older adults from disadvantaged backgrounds may score lower on memory and thinking tests because of test anxiety and stress, not because of true memory problems. This can lead to being wrongly diagnosed with dementia. This study will test whether a short, 15-minute guided meditation before taking a memory and thinking test helps older adults do better on the test and feel less stressed. About 60 adults age 50 and older, with lower education and income levels, will take part. Participants will be randomly assigned to either listen to a guided meditation or listen to a neutral story for 15 minutes before taking the test. The study will measure stress using heart rate, blood pressure, saliva samples, and a stress questionnaire.

Read the detailed description

This pilot study examines whether a brief mindfulness meditation intervention, administered immediately before cognitive testing, can reduce measurement bias caused by test-related anxiety in older adults from low-income, low-education backgrounds. Participants are randomized to a 15-minute guided mindfulness meditation session or a 15-minute neutral story-listening control session, both administered immediately before the Montreal Cognitive Assessment (MoCA). Physiological stress markers (heart rate variability, blood pressure, salivary pH) and self-reported anxiety (State-Trait Anxiety Inventory) are assessed to evaluate the intervention's effect on stress. Assessments and physiological data collection are administered via a custom application developed by the study team, which standardizes test administration and scoring.

02

Conditions studied

  • Test Anxiety
  • Stress, Psychological
  • Cognitive Aging

Browse trials for

Keywords

  • mindfulness meditation
  • MOCA
  • older adults
  • health disparities
  • test anxiety
  • heart rate variability
03

In context

Stress, Psychological

844 studies on the registry are indexed under Stress, Psychological; 136 are open to participants now.

This study's planned enrollment of 60 is below the median of 84 across 688 interventional studies indexed under Stress, Psychological.

Browse Stress, Psychological studies →

Lead sponsor

University of South Carolina is the lead sponsor of 197 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 years or older
  • Self-identified low educational attainment (high school diploma or less)
  • Low socioeconomic status per local criteria
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of dementia
  • Uncorrected hearing impairment preventing completion of the audio-guided intervention
  • Uncorrected vision impairment preventing completion of the (MoCA)
  • Current regular mindfulness meditation practice
  • Diagnosis of atrial fibrillation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Mindfulness Meditation

    Participants complete a 15-minute guided mindfulness meditation session immediately before completing the Montreal Cognitive Assessment (MoCA).

    Behavioral: Guided Mindfulness Meditation

  • Active comparator
    Story-Listening Control

    Participants listen to a 15-minute neutral, non-mindfulness story immediately before completing the Montreal Cognitive Assessment (MoCA).

    Behavioral: Neutral Story Listening

Interventions

  • BehavioralGuided Mindfulness Meditation

    A 15-minute audio-guided mindfulness meditation session delivered via the study application, administered immediately before cognitive testing.

  • BehavioralNeutral Story Listening

    A 15-minute audio recording of a neutral, non-mindfulness-based story delivered via the study application, administered once immediately before cognitive testing.

06

What researchers measure

Primary outcomes

  1. Change in MoCA Total Score

    Cognitive performance measured using the Montreal Cognitive Assessment (MoCA), ranging from 0 to 30, with higher scores indicating better cognitive performance, administered by an examiner immediately after the assigned 15-minute intervention session.

    Time frame: Immediately following the 15-minute intervention session (single study visit)

Secondary outcomes

  1. Change in Heart Rate Variability

    Change in heart rate variability measured continuously via the study application before and during the assigned intervention session.

    Time frame: Baseline to immediately post-session

  2. Change in Systolic Blood Pressure

    Change in systolic blood pressure measured via automated cuff before and immediately after the assigned intervention session.

    Time frame: Baseline to immediately post-session

  3. Change in Salivary pH

    Change in salivary pH measured via test strips before and immediately after the assigned intervention session.

    Time frame: Baseline to immediately post-session

  4. Change in State-Trait Anxiety Inventory Score

    Change in self-reported state anxiety measured using the State Anxiety subscale of the State-Trait Anxiety Inventory (STAI), a 20-item scale ranging from 20 to 80, with higher scores indicating greater state anxiety, administered at baseline and immediately after the assigned intervention session.

    Time frame: Baseline to immediately post-assessment

  5. Change in Perceived Stress Scale (PSS-10) Score

    Change in self-reported perceived stress measured using the 10-item Perceived Stress Scale (PSS-10), ranging from 0 to 40, with higher scores indicating greater perceived stress, administered at baseline and immediately after the assigned intervention session.

    Time frame: Baseline to immediately post-assessment

  6. Recruitment Rate

    Percentage of eligible individuals screened who agree to enroll in the study.

    Time frame: Up to 4 months

  7. Retention Rate

    Percentage of enrolled participants who complete their assigned study visit.

    Time frame: Day 1

  8. Intervention Adherence

    Percentage of participants who complete the full 15-minute assigned intervention session (mindfulness meditation or story-listening control), as recorded by the study application

    Time frame: Day 1

  9. Participant Acceptability

    Acceptability assessed via a 3-item investigator-developed measure: (1) enjoyment of the session, (2) comfort during the session, (3) perceived health benefit. Each item is rated on a 3-point scale (No / Neutral / Yes) and reported individually.

    Time frame: Day 1

  10. Task Feasibility (Participant-Reported)

    Feasibility assessed via a 2-item investigator-developed measure: (1) physical ease of the seated/lying position, (2) clarity of the recorded audio instructions. Each item is rated on a 3-point scale and reported individually.

    Time frame: Day 1

07

Study locations

4 sites
  • Lourie Center, Senior Resources, Inc.
    Columbia, South Carolina 29201, United States
  • University of South Carolina, Aging Gracefully Lab
    Columbia, South Carolina 29201, United States
  • Vital Aging of Williamsburg County, Inc
    Kingstree, South Carolina 29556, United States
  • Brookland-Lakeview Empowerment Center
    West Columbia, South Carolina 29169, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Data sharing plans have not yet been finalized. As a pilot study with a small sample size (n=60), the investigators will determine after study completion whether de-identified individual participant data will be made available, and if so, under what conditions (e.g., data use agreement, timeframe, and mechanism of access).

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07924904
Responsible party
Jean Neils-Strunjas (Professor and Chair, University of South Carolina) — Principal investigator
First posted
Nov 9, 2026
Start date
Nov 14, 2026 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Mina Karami, PhD Student
Contact
karamim@email.sc.edu
18032614523

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion